Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Latest findings

Before the arrival of Jevtana, Zytiga and Provenge, the median survival after Taxotere was roughly 12 months [1]. [source, 2012]
This was the rationale for the development of Zytiga and now MDV3100. [source, 2012]
Currently, three novel molecucles have been approved by the FDA and EMEA: cabazitaxel (Jevtana) and abiraterone (Zytiga) were approved for the treatment of patients with metastatic CRPC postdocetaxel, and denosumab (Xgeva) was approved for the supportive management of bone disease. [source, 2012]